Claims:

~~1. A composition of matter comprising an extract of a plurality of peanuts, wherein said peanuts are at a R5 developmental stage, wherein said extract comprises heat denatured allergenic proteins of said peanuts, wherein said composition of matter is essentially devoid of fully mature peanuts.~~

~~2. The composition of claim 1, being hypoallergenic in a subject that is allergic to the native form of said allergenic proteins.~~

~~3. A food product comprising the composition of matter of claims 1 or 2.~~

~~4. An article of manufacture comprising an aliquot of the composition of matter of claims 1 or 2, which comprises 1-10 g of peanut protein.~~

~~5. A method of generating a composition of matter comprising an extract of peanuts, the method comprising:~~

~~(a) selecting peanuts at an R5 developmental stage; (b) isolating the peanuts according to step (a) so as to generate a collection of peanuts which are devoid of mature peanuts, (c) heating said collection of peanuts for a length of time that denatures at least one allergenic protein of said peanuts, thereby generating the composition.~~

~~6. The method of claim 5, wherein said heating is carried out at a temperature between 50-500 ºC for at least 1 hour.~~

~~7. The method of claim 5, wherein said selecting is effected using x-ray technology.~~

~~8. The method of claim 5, further comprising generating a powder from said peanuts prior to said processing.~~

~~9. A composition of matter generated according to the method of any one of claims 6-8.~~

~~10~~1. Use of a peanut extract comprising denatured proteins for the manufacture of a medicament for reducing allergenicity of peanuts in an allergic subject, wherein said denatured

proteins are derived from peanuts at a R5 developmental stage, wherein said proteins are denatured by cooking or heating to a temperature between 50-500 ºC, wherein said extract is essentially devoid of fully mature peanuts.

~~11~~2. The use of claim 1~~0~~, wherein said peanut extract is formulated for oral administration.

~~12~~3. The use of claim 1~~0~~, wherein said extract is provided in an amount between 0.1 - 2 gr of protein per week.

~~13~~4. Use of a peanut extract comprising denatured proteins for the manufacture of a medicament for preventing allergenicity of peanuts in a subject, wherein said denatured proteins are derived from peanuts at a R5 developmental stage, wherein said proteins are denatured by cooking or heating to a temperature between 50-500 ºC, wherein said extract is essentially devoid of fully mature peanuts.

~~14~~5. The use of claim ~~13~~4, wherein said subject is an infant.